Skip to main content

Table 1 Overview of included studies examining the efficacy, effectiveness, and adherence of oral PrEP

From: A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?

Characteristics Number of incident HIV infections
Year Study name Geographical location Population Sample size Total follow-up time (person-years) Design Regimen Drug Study drug Placebo/ comparator Total
2010 iPrEx [6] Global MSM/TGW 2499 3324 RDBPCT Daily TDF-FTC 36 64 100
2012 Partners study [7] Kenya and Uganda Heterosexual HIV-discordant couples 4758 7820 RDBPCT Daily TDF-FTC 13 52 82
TDF 17
2012 TDF2 [8] Botswana Heterosexual 1219 1563 RDBPCT Daily TDF-FTC 9 24 33
2012 FEM-PrEP [13] Kenya, Tanzania and South Africa Heterosexual females 2120 – RDBPCT Daily TDF-FTC 33 35 68
2012 Kenya safety and adherence study [38] Kenya MSM and Female sex workers 72 – RDBPCT Daily TDF-FTC 0 1 1
Time-driven 0
2013 Partners adherence substudy [17] Kenya and Uganda Heterosexual HIV-discordant couples 1147 807 Convenience sub-cohort of a RDBPCT Daily TDF-FTC 0 14 14
TDF 0
2013 Bangkok tenofovir study [31] Bangkok PWID 2413 9665 RDBPCT Daily TDF 17 33 50
2013 Uganda safety and adherence study [35] Uganda Heterosexual HIV-discordant couples 72 – RDBPCT Daily TDF-FTC 0 0 0
Time-driven 0 0
2013 ATN 082 (Project PrEPARE) [54] United States Young MSM 58 – RBPCT Daily TDF-FTC 0 0 0
No pill 0
2014 iPrEx extension [15] Global MSM/TGW 1603 (1225 received) – Open Label Daily TDF-FTC 28 13 41
2015 VOICE [14] South Africa, Uganda, Zimbabwe Heterosexual females 3019 4253 RCT Daily TDF-FTC 61 60 173
TDF 52
2015 HPTN 067/ADAPTa [36] South Africa Heterosexual females 191 – RCT with different regimens as comparators Daily TDF-FTC 1 N/A 5
Time-driven 2
Event-driven 2
2015 Generating adherence Philadelphia [50] United States Young MSM of colour 23 7.5 Observational Daily TDF-FTC 0 N/A 0
2015 PROUD [9] United Kingdom MSM 544 465 RCT with a 1 year deferred group as comparator Daily TDF-FTC 3 20 23
2015 IPERGAY [10] France and Canada MSM/TGW 400 431 RDBPCT Event-driven TDF-FTC 2 14 16
2016 Bangkok MSMa [55] Thailand MSM /TGW 168 – Observational Daily TDF-FTC 0 N/A 0
2016 Permanente Cohort [24] USA At-risk 972 850 Open label Daily TDF-FTC 0 2 Off-PrEP 2
2016 The Demo Project [23] USA MSM/TGW 557 481 Open label Daily TDF-FTC 1 1 Off-PrEP 2
2017 SPARKa [57] United States MSM 301 – Open Label Daily TDF-FTC – – –
2017 IPERGAY extension [22] France/Canada MSM/TGW 361 518 Open label Event-driven TDF-FTC 0 1 Off-PrEP 1
2017 Short term PrEP Mozambiquea [25] Mozambique Heterosexual females 74 7.4 Open label Daily TDF-FTC 0 N/A 1
2017 Parisian MSMa [26] France MSM 785 215 Open label Daily & Event-driven TDF-FTC 3 N/A 3
2017 PRELUDEa [27, 28] Australia Gay/bisexual males 317 381 Open label Daily TDF-FTC 0 N/A 0
2017 PROUD adherencea [29] UK MSM 544 enrolled (481 initiated) 1253 Open label Daily TDF-FTC 10 N/A 10
2017 Pluspillsa [30] South Africa Adolescents 148 131 Open label Daily TDF-FTC 0 1 Off-PrEP 1
2017 Brazil Demoa [65] Brasil MSM/TGW 450 389 Open label Daily TDF-FTC 0 2 Off-PrEP 2
  1. a Abstract available only. MSM men who have sex with men, TGW transgender women, PWID people who inject drugs, RCT randomised controlled trial, RDBPCT randomised, double blinded, placebo controlled trial, TDF tenofovir, FTC emtricitabine
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us